Confirm Rx™ Versus Reveal LINQ™ - Which is More Reliable in Data Transmission? A Randomized Clinical Study

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

209 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-05-18

Study Completion Date

2020-03-09

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will compare the reliability and timeliness in data transmission of the Abbott Confirm Rx™ loop recorder with the Medtronic Reveal LINQ™ loop recorder.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Usability Study to Assess the Reveal LINQ Insertable Cardiac Monitor System

NCT01965899

Syncope Recurrent Symptomatic Atrial Fibrillation

COMPLETED NA

Magnetic Resonance (MR) Conditional Tachyarrhythmia Therapy Products Post-approval Study

NCT02849769

Tachyarrhythmia

COMPLETED

Reveal LINQ Registry

NCT02746471

Arrhythmias, Cardiac

COMPLETED

Impact of an Intensive Monitoring Strategy in Symptomatic Patients With Suspected Arrhythmia

NCT03001765

Suspected Arrhythmia

COMPLETED NA

Comparative Analysis in Detection of Atrial Arrhythmia and ECG Quality in Three Different Insertable Cardiac Monitors

NCT04471584

Arrhythmias, Cardiac

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Implantable cardiac monitor (ICM) is an invaluable tool for diagnosing cardiac arrhythmia (1). Cryptogenic stroke, unexplained syncope and arrhythmia diagnosis are the most common indication for long term cardiac monitoring device. (2, 3). Reveal LINQTM (Medtronic, Inc.) is widely used for all of these purposes in the country. We have previously reported the use of Reveal XT in the use of atrial fibrillation (AF) surveillance in patient's post-AF ablation (2). We indicated that ICM is useful in long term monitoring of atrial arrhythmia in patients at risk of atrial fibrillation. Crystal AF (4) study also showed the importance of using ICM in detecting occult AF in patients with cryptogenic stroke in a timely manner so that appropriate treatment can be prescribed. The key to the success of ICM rest on how timely and reliable the ICM data can be transmitted to physician's office immediately after an arrhythmic events so the data can be analyzed and treatment rendered. Reveal LINQTM data transmission consists of two steps: 1. Data needs to be download into the MyCareLink™ monitor (scheduled daily at 2 am in the morning and monitor needs to be in the within 6 feet proximity of the patient) 2. MyCareLink™ monitor to be connected to the 3 G cellular network for the data transmission. (Fig 1). In cases of patient activated events, data transmission utilizes similar pathway.

We have reported significant delay in data transmission in the Reveal LINQTM occurs frequently and failure to connect among the Reveal LINQTM, MyCareLink™ monitor and the cellular network is the main reason for data transmission disruption and critical data could be concealed for an extended periods. To illustrate the importance of timely transmission of patient data, a Reveal LINQTM was implanted in a 54-year-old gentle man with past medical history of recurrent syncope. On 8/12/2017 the patient developed new onset dizziness and 6 seconds sinus pause was recorded by the device. However, a connection problem of MyCarelinkTM system made data unavailable until next scheduled office visit on 11/15/2017. The physician was notified on the same day and a pacemaker was implanted on the following day, almost 3 months after his significant arrhythmic events.

The newer generation of ICM such as Confirm Rx™ (Abbott, Inc) is connected directly to a patient's existing smartphone using the Bluetooth technology. By allowing patients to record and transmit symptoms with the mobile app, Confirm Rx™ ICM brings continuous remote monitoring to patients without the need for a home-based monitor (Fig 2). It is unclear which technologies offers faster and more reliable transmission of critical patient information to physician office so timely treatment can be provided. We therefore propose a pilot randomized study comparing Confirm Rx™ and Reveal LINQTM in the reliability and timeliness in data transmission.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cardiac Arrythmias Syncope Atrial Fibrillation Atrial Flutter Tachycardia Stroke

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Abbott, Inc Confirm Rx™

Every other consenting subject will receive the Abbott Inc. Confirm Rx™ device.

Group Type ACTIVE_COMPARATOR

Abbott, Inc Confirm Rx™ versus Medtronic, Inc Reveal LINQTM

Intervention Type DEVICE

Comparing reliability and timeliness in data transmission between two implantable cardiac monitors.

Medtronic, Inc Reveal LINQTM

Every other consenting subject will receive the Medtronic, Inc. Reveal LINQTM.

Group Type ACTIVE_COMPARATOR

Abbott, Inc Confirm Rx™ versus Medtronic, Inc Reveal LINQTM

Intervention Type DEVICE

Comparing reliability and timeliness in data transmission between two implantable cardiac monitors.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Abbott, Inc Confirm Rx™ versus Medtronic, Inc Reveal LINQTM

Comparing reliability and timeliness in data transmission between two implantable cardiac monitors.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient is 18 years of age or older
* Patient is willing and able to provide written informed consent
* Patient is willing and able to comply with the protocol, including follow-up visits and MyCareLink™ and Merlin™ transmissions (standard of care)
* Candidates for implantable cardiac monitor

Exclusion Criteria

* Patient is enrolled in another study that could confound the results of this study, without documented pre-approval from a study manager
* Patient has existing IPG, ICD, CRT-D or CRT-P device
* Adequate sensing in one week post implant. If sensing not adequate, patient will be in the registry.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No